PL2889033T3 - Leczenie negatywnych objawów schizofrenii za pomocą (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu i jego farmaceutycznie dopuszczalnych soli - Google Patents

Leczenie negatywnych objawów schizofrenii za pomocą (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu i jego farmaceutycznie dopuszczalnych soli

Info

Publication number: PL2889033T3
Authority: PL; Poland
Prior art keywords: quinuclidin; schizophrenia; carboxamide; thiophene; benzo
Prior art date: 2008-11-19

Application number

PL15151165T

Other languages

English (en)

Inventor

Gerhard Koenig

Richard Chesworth

Gideon Shapiro

Original Assignee

Forum Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-19

Filing date

2009-11-19

Publication date

2018-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2889033(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-19 Application filed by Forum Pharmaceuticals Inc. filed Critical Forum Pharmaceuticals Inc.

2018-10-31 Publication of PL2889033T3 publication Critical patent/PL2889033T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL15151165T 2008-11-19 2009-11-19 Leczenie negatywnych objawów schizofrenii za pomocą (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu i jego farmaceutycznie dopuszczalnych soli PL2889033T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US11610608P	2008-11-19	2008-11-19
EP12185913.6A EP2540297B1 (en)	2008-11-19	2009-11-19	Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
EP15151165.6A EP2889033B1 (en)	2008-11-19	2009-11-19	Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
EP09756921A EP2355822B1 (en)	2008-11-19	2009-11-19	Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number	Publication Date
PL2889033T3 true PL2889033T3 (pl)	2018-10-31

Family

ID=41786120

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL12185913T PL2540297T3 (pl)	2008-11-19	2009-11-19	Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
PL15151165T PL2889033T3 (pl)	2008-11-19	2009-11-19	Leczenie negatywnych objawów schizofrenii za pomocą (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu i jego farmaceutycznie dopuszczalnych soli
PL09756921T PL2355822T3 (pl)	2008-11-19	2009-11-19	Leczenie zaburzeń funkcji poznawczych (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutycznie dopuszczalnymi solami

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL12185913T PL2540297T3 (pl)	2008-11-19	2009-11-19	Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL09756921T PL2355822T3 (pl)	2008-11-19	2009-11-19	Leczenie zaburzeń funkcji poznawczych (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutycznie dopuszczalnymi solami

Country Status (34)

Country	Link
US (6)	US8642638B2 (pl)
EP (4)	EP2889033B1 (pl)
JP (6)	JP5272080B2 (pl)
KR (3)	KR20140146216A (pl)
CN (3)	CN102281878A (pl)
AU (1)	AU2009316557B2 (pl)
BR (1)	BRPI0922057A2 (pl)
CA (3)	CA2894860C (pl)
CL (3)	CL2011001178A1 (pl)
CO (1)	CO6400190A2 (pl)
CR (1)	CR20110267A (pl)
CY (3)	CY1113671T1 (pl)
DK (3)	DK2355822T3 (pl)
EC (1)	ECSP11011076A (pl)
ES (3)	ES2673016T3 (pl)
HR (3)	HRP20130007T1 (pl)
HU (2)	HUE037938T2 (pl)
IL (5)	IL212921A (pl)
LT (1)	LT2889033T (pl)
MX (1)	MX2011005270A (pl)
MY (2)	MY173229A (pl)
NZ (2)	NZ593467A (pl)
PE (1)	PE20110711A1 (pl)
PH (2)	PH12014501629A1 (pl)
PL (3)	PL2540297T3 (pl)
PT (3)	PT2889033T (pl)
RS (1)	RS52583B (pl)
RU (3)	RU2532327C2 (pl)
SG (1)	SG10201504102QA (pl)
SI (3)	SI2889033T1 (pl)
SM (3)	SMT201800308T1 (pl)
TR (1)	TR201807944T4 (pl)
WO (1)	WO2010059844A1 (pl)
ZA (1)	ZA201104044B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
PL2540297T3 (pl)	2008-11-19	2015-12-31	Forum Pharmaceuticals Inc	Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
KR101698250B1 (ko)	2010-05-17	2017-01-19	포럼 파마슈티칼즈 인크.	(R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
WO2012074799A1 (en) *	2010-11-18	2012-06-07	Envivo Pharmaceuticals, Inc.	Treatment of inflammation with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
US20140155429A1 (en) *	2011-05-09	2014-06-05	Envivo Pharmaceuticals, Inc.	Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine
EP2725906A4 (en) *	2011-07-01	2015-02-18	Envivo Pharmaceuticals Inc	LIMIT COGNITIVE DEFICIT TREATMENT METHODS
RU2635522C2 (ru) *	2012-05-08	2017-11-13	Форум Фармасьютикалз, Инк.	Способы поддержания, лечения или улучшения когнитивной функции
CA3053916A1 (en)	2017-02-27	2018-08-30	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Anti-psychotic composition and treatment methods
WO2019060298A1 (en)	2017-09-19	2019-03-28	Neuroenhancement Lab, LLC	METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en)	2017-12-04	2023-08-08	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en)	2017-12-31	2022-05-03	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en)	2017-12-31	2025-04-22	NeuroLight, Inc.	Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en)	2018-04-20	2022-06-21	Neuroenhancement Lab, LLC	System and method for inducing sleep by transplanting mental states
CN113382683A (zh)	2018-09-14	2021-09-10	纽罗因恒思蒙特实验有限责任公司	改善睡眠的系统和方法

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5122528A (en)	1983-12-22	1992-06-16	Erbamont, Inc.	Analgesic use of benzobicyclic carboxamides
US4605652A (en)	1985-02-04	1986-08-12	A. H. Robins Company, Inc.	Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (de)	1985-03-14	1993-11-04	Beecham Group Plc	Arzneimittel zur behandlung von erbrechen.
NL8701682A (nl)	1986-07-30	1988-02-16	Sandoz Ag	Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3827253A1 (de)	1987-08-20	1989-03-02	Sandoz Ag	Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de)	1987-12-03	1989-06-15	Sandoz Ag	N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
US5198437A (en)	1987-12-10	1993-03-30	Duphar International Research B.V.	1,7-annelated indolecarboxylic acid esters and amides
ZA889166B (en)	1987-12-10	1990-05-30	Duphar Int Res	1,7-annelated indolecarboxylic acid esters and -amides
US4863919A (en)	1988-02-01	1989-09-05	A. H. Robins Company, Incorporated	Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de)	1988-03-29	1989-10-19	Sandoz Ag	Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en)	1988-08-04	1990-02-07	Synthelabo	Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en)	1989-01-06	1995-02-22	Elan Corp Plc	Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en)	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists
US5114947A (en)	1990-12-27	1992-05-19	Erbamont Inc.	Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de)	1991-05-10	1992-11-12	Merck Patent Gmbh	Indolderivate
SE9201478D0 (sv)	1992-05-11	1992-05-11	Kabi Pharmacia Ab	Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en)	1992-08-31	1999-11-02	University Of Florida	Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
SK282366B6 (sk)	1994-08-24	2002-01-07	Astra Aktiebolag	Spiro-azabicyklická zlúčenina, farmaceutický prípravok s jej obsahom, spôsob prípravy, medziprodukty tohto spôsobu a jej použitie v medicíne
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5703116A (en)	1995-04-18	1997-12-30	Geron Corporation	Telomerase Inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
GB9606736D0 (en)	1996-02-19	1996-06-05	Shire International Licensing	Therapeutic method
FR2756826B1 (fr)	1996-12-05	1999-01-08	Adir	Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SK284994B6 (sk)	1997-05-30	2006-04-06	Neurosearch A/S	Deriváty 8-azabicyklo[3.2.1]okt-2-énu, spôsob ich prípravy a ich použitie
US7214686B2 (en)	1997-06-30	2007-05-08	Targacept, Inc.	Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja)	1997-09-12	1999-03-23	Dai Ichi Seiyaku Co Ltd	向知性薬
US6875606B1 (en)	1997-10-23	2005-04-05	The United States Of America As Represented By The Department Of Veterans Affairs	Human α-7 nicotinic receptor promoter
US6277870B1 (en)	1998-05-04	2001-08-21	Astra Ab	Use
AU6394399A (en)	1998-09-18	2000-04-10	Rockefeller University, The	Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
US6953855B2 (en)	1998-12-11	2005-10-11	Targacept, Inc.	3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en)	1998-12-11	2002-08-13	Targacept, Inc.	Pharmaceutical compositions and methods for use
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds
FR2790474B1 (fr)	1999-03-05	2001-04-06	Synthelabo	Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr)	1999-03-30	2001-05-04	Synthelabo	Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en)	1999-11-08	2002-07-09	Research Triangle Institute	Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
EP1233979A1 (en)	1999-12-01	2002-08-28	Ortho-McNeil Pharmaceutical, Inc.	Method of diagnosing neurodegenerative disease
CA2393538A1 (en)	1999-12-14	2001-06-21	Pharmacia & Upjohn Company	Human ion channels
FR2804430B1 (fr)	2000-01-28	2002-03-22	Sanofi Synthelabo	Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en)	2000-05-05	2000-06-28	Novartis Ag	Organic compounds
EP1287001B1 (en)	2000-06-06	2004-09-29	Pfizer Products Inc.	Thiophene derivatives useful as anticancer agents
TW593223B (en)	2000-06-20	2004-06-21	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr)	2000-06-27	2004-12-24	Adir	Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja)	2000-07-18	2011-01-19	田辺三菱製薬株式会社	１−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en)	2000-08-14	2003-05-15	Lee Daniel H. S.	Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
WO2002016356A2 (en)	2000-08-18	2002-02-28	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
EP1381603A2 (en)	2000-08-18	2004-01-21	PHARMACIA & UPJOHN COMPANY	Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6492385B2 (en)	2000-08-18	2002-12-10	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en)	2000-08-21	2002-12-31	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10044905A1 (de)	2000-09-12	2002-03-21	Merck Patent Gmbh	(2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en)	2000-12-29	2002-07-04	O'neill Brian Thomas	Pharmaceutical composition for the treatment of CNS and other disorders
ATE348829T1 (de)	2001-02-06	2007-01-15	Pfizer Prod Inc	Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
GB0108337D0 (en)	2001-04-03	2001-05-23	Novartis Ag	Organic compounds
US6569865B2 (en)	2001-06-01	2003-05-27	Astrazeneca Ab	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es)	2001-06-12	2004-08-04	Upjohn Co	Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
WO2003018586A1 (en)	2001-08-24	2003-03-06	Pharmacia & Upjohn Company	Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
JP2003081978A (ja)	2001-09-10	2003-03-19	Mitsubishi Pharma Corp	スピロ環式化合物およびその医薬用途
US20030105089A1 (en)	2001-09-12	2003-06-05	Wishka Donn G.	Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
AP1635A (en)	2001-10-02	2006-07-14	Upjohn Co	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
EP1438308A1 (en)	2001-10-26	2004-07-21	PHARMACIA & UPJOHN COMPANY	N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
JP2005511613A (ja)	2001-11-08	2005-04-28	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	疾患治療用アザビシクロ置換ヘテロアリール化合物
MXPA04004373A (es)	2001-11-09	2004-08-11	Upjohn Co	Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
GB0127008D0 (en)	2001-11-09	2002-01-02	Novartis Ag	Organic compounds
DE10156719A1 (de)	2001-11-19	2003-05-28	Bayer Ag	Heteroarylcarbonsäureamide
FR2832714B1 (fr)	2001-11-23	2004-07-16	Sanofi Synthelabo	Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832712B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
NZ533259A (en)	2001-12-14	2007-10-26	Targacept Inc	Methods and compositions for treatment of central nervous system disorders
DE10162442A1 (de)	2001-12-19	2003-07-03	Bayer Ag	Monocyclische N-Aryl-amide
DE10162375A1 (de)	2001-12-19	2003-07-10	Bayer Ag	Bicyclische N-Aryl-amide
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
BR0307714A (pt)	2002-02-15	2005-02-09	Upjohn Co	Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
AU2003219690A1 (en)	2002-02-19	2003-09-09	Pharmacia And Upjohn Company	Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
EP1476448A2 (en)	2002-02-19	2004-11-17	PHARMACIA & UPJOHN COMPANY	Azabicyclic compounds for the treatment of disease
AU2003214936A1 (en)	2002-02-20	2003-09-09	Pharmacia And Upjohn Company	Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Bicyclische N-Biarylamide
DE10211416A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Essig- und Propionsäureamide
US20030236287A1 (en)	2002-05-03	2003-12-25	Piotrowski David W.	Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2003095976A2 (en)	2002-05-09	2003-11-20	Memory Pharmaceuticals Corporation	Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
JP2006503811A (ja)	2002-07-17	2006-02-02	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブとの組み合わせ
DE10234424A1 (de)	2002-07-29	2004-02-12	Bayer Ag	Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003249532A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
GB0220581D0 (en) *	2002-09-04	2002-10-09	Novartis Ag	Organic Compound
PL210065B1 (pl)	2002-09-25	2011-11-30	Memory Pharm Corp	Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
PL377777A1 (pl)	2002-12-11	2006-02-20	Pharmacia & Upjohn Company Llc	Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
US20050031651A1 (en)	2002-12-24	2005-02-10	Francine Gervais	Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004085433A2 (en)	2003-03-28	2004-10-07	Pharmacia & Upjohn Company Llc	Positive allosteric modulators of the nicotinic acetylcholine receptor
US20050119249A1 (en)	2003-12-02	2005-06-02	Erik Buntinx	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en)	2003-12-22	2005-11-03	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
EP1735306A2 (en)	2004-03-25	2006-12-27	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
JP2008523058A (ja)	2004-12-10	2008-07-03	アボット・ラボラトリーズ	縮合ビシクロ複素環置換キヌクリジン誘導体
WO2007038367A1 (en)	2005-09-23	2007-04-05	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
ES2555803T3 (es)	2006-10-23	2016-01-08	Cephalon, Inc.	Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
GEP20125405B (en)	2007-05-11	2012-02-27	Pfizer	Amino-heterocyclic compounds
AR068121A1 (es)	2007-08-31	2009-11-04	Eisai R&D Man Co Ltd	Compuestos multiciclicos para tratar enfermedades neurodegenerativas
US7935815B2 (en)	2007-08-31	2011-05-03	Eisai R&D Management Co., Ltd.	Imidazoyl pyridine compounds and salts thereof
ATE503754T1 (de)	2007-10-01	2011-04-15	Comentis Inc	1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
BRPI0820418A2 (pt)	2007-11-21	2015-05-19	Abbott Lab	"derivados de alcano azabicíclico substituído com biarila como moduladores da atividade do receptor nicotínico de acetilcolina"
EA019571B1 (ru)	2008-04-29	2014-04-30	Фарнекст	Применение сульфизоксазола для лечения болезни альцгеймера
CA2722453C (en)	2008-04-29	2018-03-20	Pharnext	New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
NZ589304A (en)	2008-04-29	2012-03-30	Pharnext	Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
BRPI0920927A2 (pt)	2008-11-13	2019-09-24	Link Medicine Corp	derivados de azaquinolinona e usos dos mesmos
PL2540297T3 (pl)	2008-11-19	2015-12-31	Forum Pharmaceuticals Inc	Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
US8674095B2 (en)	2008-12-19	2014-03-18	Afraxis Holdings, Inc.	Compounds for treating neuropsychiatric conditions
WO2010075635A1 (en)	2008-12-30	2010-07-08	Ramot At Tel Aviv University Ltd.	Combination therapies using nap
TWI404721B (zh)	2009-01-26	2013-08-11	Pfizer	胺基－雜環化合物
EP3395372B1 (en)	2009-02-20	2022-04-06	EnhanX Biopharm Inc.	Glutathione-based drug delivery system
CN102333777B (zh)	2009-02-26	2014-06-25	卫材R&D管理有限公司	含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
DK2419104T3 (en)	2009-04-13	2018-02-05	Theravance Biopharma R&D Ip Llc	Combinations of 5-HT4 Receptor Agonists and Acetylcholinesterase Inhibitors to Treat Cognitive Disorders
JP2012529432A (ja)	2009-06-05	2012-11-22	リンク・メディスン・コーポレーション	アミノピロリジノン誘導体及びその使用
WO2011057199A1 (en)	2009-11-06	2011-05-12	Adenios, Inc.	Compositions for treating cns disorders
US20110274628A1 (en)	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions

2009
- 2009-11-19 PL PL12185913T patent/PL2540297T3/pl unknown
- 2009-11-19 US US13/129,782 patent/US8642638B2/en not_active Expired - Fee Related
- 2009-11-19 CN CN2009801546937A patent/CN102281878A/zh active Pending
- 2009-11-19 MX MX2011005270A patent/MX2011005270A/es active IP Right Grant
- 2009-11-19 HU HUE15151165A patent/HUE037938T2/hu unknown
- 2009-11-19 SM SM20180308T patent/SMT201800308T1/it unknown
- 2009-11-19 PT PT151511656T patent/PT2889033T/pt unknown
- 2009-11-19 CA CA2894860A patent/CA2894860C/en not_active Expired - Fee Related
- 2009-11-19 JP JP2011537621A patent/JP5272080B2/ja not_active Expired - Fee Related
- 2009-11-19 WO PCT/US2009/065173 patent/WO2010059844A1/en not_active Ceased
- 2009-11-19 TR TR2018/07944T patent/TR201807944T4/tr unknown
- 2009-11-19 SG SG10201504102QA patent/SG10201504102QA/en unknown
- 2009-11-19 AU AU2009316557A patent/AU2009316557B2/en not_active Ceased
- 2009-11-19 HR HRP20130007AT patent/HRP20130007T1/hr unknown
- 2009-11-19 MY MYPI2014003208A patent/MY173229A/en unknown
- 2009-11-19 RS RS20120560A patent/RS52583B/sr unknown
- 2009-11-19 CN CN201610020803.2A patent/CN105687190A/zh active Pending
- 2009-11-19 LT LTEP15151165.6T patent/LT2889033T/lt unknown
- 2009-11-19 ES ES15151165.6T patent/ES2673016T3/es active Active
- 2009-11-19 NZ NZ593467A patent/NZ593467A/xx not_active IP Right Cessation
- 2009-11-19 SI SI200931855T patent/SI2889033T1/en unknown
- 2009-11-19 HU HUE12185913A patent/HUE026815T2/en unknown
- 2009-11-19 DK DK09756921.4T patent/DK2355822T3/da active
- 2009-11-19 MY MYPI2011002245A patent/MY159826A/en unknown
- 2009-11-19 EP EP15151165.6A patent/EP2889033B1/en active Active
- 2009-11-19 DK DK12185913.6T patent/DK2540297T3/en active
- 2009-11-19 KR KR1020147032489A patent/KR20140146216A/ko not_active Ceased
- 2009-11-19 RU RU2011124515/15A patent/RU2532327C2/ru not_active IP Right Cessation
- 2009-11-19 CA CA3017886A patent/CA3017886A1/en not_active Abandoned
- 2009-11-19 EP EP12185913.6A patent/EP2540297B1/en active Active
- 2009-11-19 BR BRPI0922057A patent/BRPI0922057A2/pt not_active Application Discontinuation
- 2009-11-19 DK DK15151165.6T patent/DK2889033T3/en active
- 2009-11-19 EP EP09756921A patent/EP2355822B1/en active Active
- 2009-11-19 SI SI200931223T patent/SI2540297T1/sl unknown
- 2009-11-19 ES ES12185913.6T patent/ES2541528T3/es active Active
- 2009-11-19 KR KR1020117013996A patent/KR20110091549A/ko not_active Ceased
- 2009-11-19 SI SI200930466T patent/SI2355822T1/sl unknown
- 2009-11-19 EP EP18152484.4A patent/EP3357495B1/en active Active
- 2009-11-19 NZ NZ613291A patent/NZ613291A/en not_active IP Right Cessation
- 2009-11-19 PT PT121859136T patent/PT2540297E/pt unknown
- 2009-11-19 PT PT97569214T patent/PT2355822E/pt unknown
- 2009-11-19 KR KR1020187002503A patent/KR20180011888A/ko not_active Ceased
- 2009-11-19 PE PE2011001056A patent/PE20110711A1/es not_active Application Discontinuation
- 2009-11-19 CA CA2744278A patent/CA2744278C/en not_active Expired - Fee Related
- 2009-11-19 ES ES09756921T patent/ES2396300T3/es active Active
- 2009-11-19 CN CN201610021941.2A patent/CN105687191A/zh active Pending
- 2009-11-19 PL PL15151165T patent/PL2889033T3/pl unknown
- 2009-11-19 PL PL09756921T patent/PL2355822T3/pl unknown
2011
- 2011-05-16 IL IL212921A patent/IL212921A/en not_active IP Right Cessation
- 2011-05-19 CL CL2011001178A patent/CL2011001178A1/es unknown
- 2011-05-19 CO CO11061800A patent/CO6400190A2/es not_active Application Discontinuation
- 2011-05-20 CR CR20110267A patent/CR20110267A/es unknown
- 2011-05-23 EC EC2011011076A patent/ECSP11011076A/es unknown
- 2011-05-31 ZA ZA2011/04044A patent/ZA201104044B/en unknown
2012
- 2012-11-12 US US13/674,290 patent/US8569354B2/en not_active Expired - Fee Related
2013
- 2013-01-07 CY CY20131100013T patent/CY1113671T1/el unknown
- 2013-01-09 SM SM201300003T patent/SMT201300003B/xx unknown
- 2013-04-17 JP JP2013086454A patent/JP5674854B2/ja not_active Expired - Fee Related
- 2013-12-23 US US14/139,178 patent/US20140148479A1/en not_active Abandoned
2014
- 2014-02-07 US US14/175,654 patent/US8815933B2/en not_active Expired - Fee Related
- 2014-06-04 RU RU2014122858A patent/RU2662560C2/ru not_active IP Right Cessation
- 2014-07-17 PH PH12014501629A patent/PH12014501629A1/en unknown
- 2014-10-08 US US14/509,305 patent/US20150265583A1/en not_active Abandoned
- 2014-11-26 JP JP2014238660A patent/JP5869653B2/ja not_active Expired - Fee Related
2015
- 2015-07-01 HR HRP20150711TT patent/HRP20150711T1/hr unknown
- 2015-07-02 CY CY20151100575T patent/CY1116460T1/el unknown
- 2015-07-10 SM SM201500167T patent/SMT201500167B/xx unknown
- 2015-10-12 IL IL242034A patent/IL242034A/en not_active IP Right Cessation
- 2015-10-12 IL IL242035A patent/IL242035A0/en unknown
2016
- 2016-01-07 JP JP2016001812A patent/JP6223480B2/ja not_active Expired - Fee Related
2017
- 2017-07-18 CL CL2017001853A patent/CL2017001853A1/es unknown
- 2017-10-03 JP JP2017193867A patent/JP2018039818A/ja active Pending
- 2017-10-27 US US15/796,475 patent/US20180271844A1/en not_active Abandoned
- 2017-12-06 IL IL256140A patent/IL256140A/en unknown
- 2017-12-14 IL IL256313A patent/IL256313A/en unknown
2018
- 2018-01-03 PH PH12018500023A patent/PH12018500023A1/en unknown
- 2018-05-25 CL CL2018001420A patent/CL2018001420A1/es unknown
- 2018-06-18 HR HRP20180942TT patent/HRP20180942T1/hr unknown
- 2018-06-20 CY CY20181100638T patent/CY1121607T1/el unknown
- 2018-07-11 RU RU2018125456A patent/RU2018125456A/ru unknown
2019
- 2019-11-22 JP JP2019210985A patent/JP2020040977A/ja active Pending

Also Published As

Publication number	Publication date
CL2011001178A1 (es)	2011-10-14
HRP20130007T1 (hr)	2013-01-31
RS52583B (sr)	2013-04-30
JP2020040977A (ja)	2020-03-19
HRP20180942T1 (hr)	2018-08-10
CO6400190A2 (es)	2012-03-15
PE20110711A1 (es)	2011-10-11
PH12014501629B1 (en)	2016-01-18
CL2018001420A1 (es)	2018-09-28
JP2015083574A (ja)	2015-04-30
US8815933B2 (en)	2014-08-26
AU2009316557A1 (en)	2010-05-27
RU2011124515A (ru)	2012-12-27
US20130137717A1 (en)	2013-05-30
IL242034A (en)	2017-12-31
BRPI0922057A2 (pt)	2015-12-15
DK2889033T3 (en)	2018-07-02
IL212921A (en)	2015-11-30
PH12014501629A1 (en)	2016-01-18
CY1121607T1 (el)	2020-05-29
CA3017886A1 (en)	2010-05-27
JP5674854B2 (ja)	2015-02-25
ES2673016T3 (es)	2018-06-19
US20110288119A1 (en)	2011-11-24
CN102281878A (zh)	2011-12-14
SMT201300003B (it)	2013-05-06
JP2018039818A (ja)	2018-03-15
LT2889033T (lt)	2018-07-10
EP2540297A1 (en)	2013-01-02
US20140155430A1 (en)	2014-06-05
EP2355822A1 (en)	2011-08-17
CN105687191A (zh)	2016-06-22
JP2012509347A (ja)	2012-04-19
EP2355822B1 (en)	2012-10-10
SI2540297T1 (sl)	2015-08-31
CL2017001853A1 (es)	2018-05-11
TR201807944T4 (tr)	2018-06-21
PL2355822T3 (pl)	2013-03-29
CN105687190A (zh)	2016-06-22
EP2889033A1 (en)	2015-07-01
ECSP11011076A (es)	2011-09-30
MX2011005270A (es)	2011-08-03
SG10201504102QA (en)	2015-06-29
MY173229A (en)	2020-01-07
DK2355822T3 (da)	2013-01-28
EP3357495B1 (en)	2019-12-25
ES2396300T3 (es)	2013-02-20
CA2744278C (en)	2015-09-08
CA2894860A1 (en)	2010-05-27
AU2009316557B2 (en)	2015-08-27
CR20110267A (es)	2011-10-13
SMT201800308T1 (it)	2018-09-13
SI2889033T1 (en)	2018-08-31
SMT201500167B (it)	2015-09-07
KR20180011888A (ko)	2018-02-02
PT2889033T (pt)	2018-06-18
ES2541528T3 (es)	2015-07-21
EP2889033B1 (en)	2018-03-21
US20140148479A1 (en)	2014-05-29
KR20110091549A (ko)	2011-08-11
RU2014122858A (ru)	2015-12-10
MY159826A (en)	2017-02-15
RU2532327C2 (ru)	2014-11-10
JP5272080B2 (ja)	2013-08-28
RU2662560C2 (ru)	2018-07-26
JP2013166771A (ja)	2013-08-29
SI2355822T1 (sl)	2013-02-28
JP6223480B2 (ja)	2017-11-01
EP2540297B1 (en)	2015-04-08
PL2540297T3 (pl)	2015-12-31
HRP20150711T1 (hr)	2015-08-14
ZA201104044B (en)	2012-11-28
CY1116460T1 (el)	2017-03-15
NZ613291A (en)	2014-11-28
CY1113671T1 (el)	2016-07-27
IL256313A (en)	2018-02-28
US8642638B2 (en)	2014-02-04
NZ593467A (en)	2013-07-26
PT2355822E (pt)	2013-01-14
CA2894860C (en)	2018-11-06
US8569354B2 (en)	2013-10-29
US20150265583A1 (en)	2015-09-24
CA2744278A1 (en)	2010-05-27
PT2540297E (pt)	2015-08-26
HK1158520A1 (en)	2012-07-20
HUE037938T2 (hu)	2018-09-28
WO2010059844A1 (en)	2010-05-27
IL212921A0 (en)	2011-07-31
JP2016128442A (ja)	2016-07-14
DK2540297T3 (en)	2015-07-13
HUE026815T2 (en)	2016-07-28
RU2018125456A (ru)	2020-01-13
EP3357495A1 (en)	2018-08-08
IL242034A0 (en)	2015-11-30
US20180271844A1 (en)	2018-09-27
PH12018500023A1 (en)	2019-07-15
IL256140A (en)	2018-02-28
KR20140146216A (ko)	2014-12-24
JP5869653B2 (ja)	2016-02-24
IL242035A0 (en)	2015-11-30

Publication	Publication Date	Title
HUE037938T2 (hu)	2018-09-28	Skizofrénia negatív tüneteinek kezelése (R)-7-klór-N-(kinuklidin-3-il)benzo[b]tiofén-2-karboxamiddal és ennek gyógyszerészetileg elfogadható sójával
NZ603625A (en)	2014-10-31	A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
IL211279A (en)	2015-03-31	Use of the tspan12 antagonist in the preparation of a blood vessel inhibition drug
HUP0700369A2 (en)	2009-04-28	Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en)	2009-04-28	Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
EP2121729A4 (en)	2013-07-31	PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF
EP2386301A4 (en)	2012-07-18	PHARMACEUTICAL COMPOSITION OF LEVOAMLOPIDINE OR PHARMACEUTICAL ACCEPTABLE SALTS AND BETA BLOCKERS, AND USE THEREOF
ZA200900556B (en)	2009-12-30	Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders